Management and risk factors of recurrent gestational trophoblastic neoplasia: An update from 2004 to 2017
Abstract Objective We investigated the clinical characteristics, treatments, and survival of patients with gestational trophoblastic neoplasia (GTN) who experienced recurrence. Factors predictive of recurrence were also investigated. Methods Patients with GTN who recurred after completing chemothera...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2020-04-01
|
| Series: | Cancer Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cam4.2901 |
| _version_ | 1819099407994322944 |
|---|---|
| author | Yujia Kong Liju Zong Hongyan Cheng Fang Jiang Xirun Wan Fengzhi Feng Tong Ren Jun Zhao Junjun Yang Yang Xiang |
| author_facet | Yujia Kong Liju Zong Hongyan Cheng Fang Jiang Xirun Wan Fengzhi Feng Tong Ren Jun Zhao Junjun Yang Yang Xiang |
| author_sort | Yujia Kong |
| collection | DOAJ |
| description | Abstract Objective We investigated the clinical characteristics, treatments, and survival of patients with gestational trophoblastic neoplasia (GTN) who experienced recurrence. Factors predictive of recurrence were also investigated. Methods Patients with GTN who recurred after completing chemotherapy at Peking Union Medical College Hospital Trophoblastic Disease Center were identified between January 2004 and December 2017. Logistic regression analysis was used to identify factors predictive of GTN recurrence. Results A total of 1827 patients with GTN achieved complete remission (CR) at our center, of whom 118 (6.5%) experienced recurrence during follow‐up. The recurrence rates for patients initially treated at our center and those referred to us were 2.7% and 14.6%, respectively. The majority of recurrent patients received floxuridine‐based multiagent chemotherapy (n = 64). Patients who underwent surgery achieved a significantly higher CR rate than those who did not (88.6% vs 61.1%, P = .001). Although 94.1% of recurrent patients reachieved CR, 33.3% of them recurred for a second time. The 5‐year survival rate of the entire cohort was 80.4%. An interval between antecedent pregnancy and chemotherapy >12 months (OR: 6.600, 95% CI [3.217‐13.540], P < .001), and an interval from first chemotherapy to achieving β‐human chorionic gonadotropin (β‐hCG) normalization >14 weeks (OR: 2.226, 95% CI [1.080‐4.588], P = .030) were predictors of recurrence. Conclusions Patients with recurrent GTN are prone to recurring for a second time. Surgery plays a beneficial role in the management of recurrent GTN. An interval between antecedent pregnancy and chemotherapy >12 months, and an interval from first chemotherapy to achieving β‐hCG normalization >14 weeks were predictors of recurrence. |
| first_indexed | 2024-12-22T00:46:24Z |
| format | Article |
| id | doaj.art-d9c1243b8694486b954a654e98bbf252 |
| institution | Directory Open Access Journal |
| issn | 2045-7634 |
| language | English |
| last_indexed | 2024-12-22T00:46:24Z |
| publishDate | 2020-04-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cancer Medicine |
| spelling | doaj.art-d9c1243b8694486b954a654e98bbf2522022-12-21T18:44:33ZengWileyCancer Medicine2045-76342020-04-01972590259910.1002/cam4.2901Management and risk factors of recurrent gestational trophoblastic neoplasia: An update from 2004 to 2017Yujia Kong0Liju Zong1Hongyan Cheng2Fang Jiang3Xirun Wan4Fengzhi Feng5Tong Ren6Jun Zhao7Junjun Yang8Yang Xiang9Department of Obstetrics and Gynecology Peking Union Medical College Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Beijing ChinaDepartment of Obstetrics and Gynecology Peking Union Medical College Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Beijing ChinaDepartment of Obstetrics and Gynecology Peking Union Medical College Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Beijing ChinaDepartment of Obstetrics and Gynecology Peking Union Medical College Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Beijing ChinaDepartment of Obstetrics and Gynecology Peking Union Medical College Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Beijing ChinaDepartment of Obstetrics and Gynecology Peking Union Medical College Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Beijing ChinaDepartment of Obstetrics and Gynecology Peking Union Medical College Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Beijing ChinaDepartment of Obstetrics and Gynecology Peking Union Medical College Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Beijing ChinaDepartment of Obstetrics and Gynecology Peking Union Medical College Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Beijing ChinaDepartment of Obstetrics and Gynecology Peking Union Medical College Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Beijing ChinaAbstract Objective We investigated the clinical characteristics, treatments, and survival of patients with gestational trophoblastic neoplasia (GTN) who experienced recurrence. Factors predictive of recurrence were also investigated. Methods Patients with GTN who recurred after completing chemotherapy at Peking Union Medical College Hospital Trophoblastic Disease Center were identified between January 2004 and December 2017. Logistic regression analysis was used to identify factors predictive of GTN recurrence. Results A total of 1827 patients with GTN achieved complete remission (CR) at our center, of whom 118 (6.5%) experienced recurrence during follow‐up. The recurrence rates for patients initially treated at our center and those referred to us were 2.7% and 14.6%, respectively. The majority of recurrent patients received floxuridine‐based multiagent chemotherapy (n = 64). Patients who underwent surgery achieved a significantly higher CR rate than those who did not (88.6% vs 61.1%, P = .001). Although 94.1% of recurrent patients reachieved CR, 33.3% of them recurred for a second time. The 5‐year survival rate of the entire cohort was 80.4%. An interval between antecedent pregnancy and chemotherapy >12 months (OR: 6.600, 95% CI [3.217‐13.540], P < .001), and an interval from first chemotherapy to achieving β‐human chorionic gonadotropin (β‐hCG) normalization >14 weeks (OR: 2.226, 95% CI [1.080‐4.588], P = .030) were predictors of recurrence. Conclusions Patients with recurrent GTN are prone to recurring for a second time. Surgery plays a beneficial role in the management of recurrent GTN. An interval between antecedent pregnancy and chemotherapy >12 months, and an interval from first chemotherapy to achieving β‐hCG normalization >14 weeks were predictors of recurrence.https://doi.org/10.1002/cam4.2901chemotherapygestational trophoblastic neoplasiarecurrencesurgerysurvival rate |
| spellingShingle | Yujia Kong Liju Zong Hongyan Cheng Fang Jiang Xirun Wan Fengzhi Feng Tong Ren Jun Zhao Junjun Yang Yang Xiang Management and risk factors of recurrent gestational trophoblastic neoplasia: An update from 2004 to 2017 Cancer Medicine chemotherapy gestational trophoblastic neoplasia recurrence surgery survival rate |
| title | Management and risk factors of recurrent gestational trophoblastic neoplasia: An update from 2004 to 2017 |
| title_full | Management and risk factors of recurrent gestational trophoblastic neoplasia: An update from 2004 to 2017 |
| title_fullStr | Management and risk factors of recurrent gestational trophoblastic neoplasia: An update from 2004 to 2017 |
| title_full_unstemmed | Management and risk factors of recurrent gestational trophoblastic neoplasia: An update from 2004 to 2017 |
| title_short | Management and risk factors of recurrent gestational trophoblastic neoplasia: An update from 2004 to 2017 |
| title_sort | management and risk factors of recurrent gestational trophoblastic neoplasia an update from 2004 to 2017 |
| topic | chemotherapy gestational trophoblastic neoplasia recurrence surgery survival rate |
| url | https://doi.org/10.1002/cam4.2901 |
| work_keys_str_mv | AT yujiakong managementandriskfactorsofrecurrentgestationaltrophoblasticneoplasiaanupdatefrom2004to2017 AT lijuzong managementandriskfactorsofrecurrentgestationaltrophoblasticneoplasiaanupdatefrom2004to2017 AT hongyancheng managementandriskfactorsofrecurrentgestationaltrophoblasticneoplasiaanupdatefrom2004to2017 AT fangjiang managementandriskfactorsofrecurrentgestationaltrophoblasticneoplasiaanupdatefrom2004to2017 AT xirunwan managementandriskfactorsofrecurrentgestationaltrophoblasticneoplasiaanupdatefrom2004to2017 AT fengzhifeng managementandriskfactorsofrecurrentgestationaltrophoblasticneoplasiaanupdatefrom2004to2017 AT tongren managementandriskfactorsofrecurrentgestationaltrophoblasticneoplasiaanupdatefrom2004to2017 AT junzhao managementandriskfactorsofrecurrentgestationaltrophoblasticneoplasiaanupdatefrom2004to2017 AT junjunyang managementandriskfactorsofrecurrentgestationaltrophoblasticneoplasiaanupdatefrom2004to2017 AT yangxiang managementandriskfactorsofrecurrentgestationaltrophoblasticneoplasiaanupdatefrom2004to2017 |